KR20110021919A - 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법 - Google Patents

인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법 Download PDF

Info

Publication number
KR20110021919A
KR20110021919A KR1020107028871A KR20107028871A KR20110021919A KR 20110021919 A KR20110021919 A KR 20110021919A KR 1020107028871 A KR1020107028871 A KR 1020107028871A KR 20107028871 A KR20107028871 A KR 20107028871A KR 20110021919 A KR20110021919 A KR 20110021919A
Authority
KR
South Korea
Prior art keywords
binding
antigen
binding protein
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107028871A
Other languages
English (en)
Korean (ko)
Inventor
레어드 블룸
다빈더 길
율리아 부그메이스터
데보라 에이 영
마고트 오툴
헤쓰 엠 궤이
카리사 케이 애드킨스
아미 아를렌 웨버
사드하나 자인
마야 아라이
Original Assignee
와이어쓰 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 엘엘씨 filed Critical 와이어쓰 엘엘씨
Publication of KR20110021919A publication Critical patent/KR20110021919A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020107028871A 2008-05-23 2009-05-26 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법 Withdrawn KR20110021919A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5554308P 2008-05-23 2008-05-23
US61/055,543 2008-05-23
US9947608P 2008-09-23 2008-09-23
US61/099,476 2008-09-23

Publications (1)

Publication Number Publication Date
KR20110021919A true KR20110021919A (ko) 2011-03-04

Family

ID=41092124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028871A Withdrawn KR20110021919A (ko) 2008-05-23 2009-05-26 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법

Country Status (13)

Country Link
US (2) US8178097B2 (https=)
EP (1) EP2296689A1 (https=)
JP (1) JP2011520989A (https=)
KR (1) KR20110021919A (https=)
CN (1) CN102149403A (https=)
AR (1) AR072136A1 (https=)
AU (1) AU2009248812A1 (https=)
BR (1) BRPI0912998A2 (https=)
CA (1) CA2725154A1 (https=)
IL (1) IL209455A0 (https=)
MX (1) MX2010012812A (https=)
RU (1) RU2010152689A (https=)
WO (1) WO2009143526A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012138A1 (ko) * 2011-07-20 2013-01-24 주식회사 에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
KR20200058653A (ko) * 2018-11-19 2020-05-28 한국생명공학연구원 신규한 il-15-il-21 융합 폴리펩티드 및 이의 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
CN102532320A (zh) * 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20200400688A1 (en) * 2018-02-13 2020-12-24 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
AU2020324185A1 (en) * 2019-08-02 2022-03-03 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-PD-1 antibody and medical use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2026067713A1 (zh) * 2024-09-29 2026-04-02 四川科伦博泰生物医药股份有限公司 抗体药物偶联物，及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1881070B1 (en) 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2276795T3 (es) 2000-05-11 2007-07-01 Genetics Institute, Llc Mu-1, miembro de la familia del receptor de citoquina.
DK1451322T3 (da) * 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
CN1688340A (zh) * 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
CA2518371A1 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012138A1 (ko) * 2011-07-20 2013-01-24 주식회사 에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
KR20200058653A (ko) * 2018-11-19 2020-05-28 한국생명공학연구원 신규한 il-15-il-21 융합 폴리펩티드 및 이의 용도

Also Published As

Publication number Publication date
AR072136A1 (es) 2010-08-11
CA2725154A1 (en) 2009-11-26
AU2009248812A1 (en) 2009-11-26
JP2011520989A (ja) 2011-07-21
WO2009143526A1 (en) 2009-11-26
EP2296689A1 (en) 2011-03-23
RU2010152689A (ru) 2012-06-27
CN102149403A (zh) 2011-08-10
MX2010012812A (es) 2011-01-21
IL209455A0 (en) 2011-01-31
US20120276102A1 (en) 2012-11-01
US20090298081A1 (en) 2009-12-03
BRPI0912998A2 (pt) 2015-10-13
US8178097B2 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
AU2018311079B2 (en) Interleukin-21 muteins and methods of treatment
KR102572091B1 (ko) 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도
US9663580B2 (en) Antibodies against human CSF-1R and uses thereof
US20230416385A1 (en) Bispecific antibody and use thereof
KR20110021919A (ko) 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
JP2016507523A (ja) ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
JP2022527372A (ja) 抗インテグリン抗体及びそれらの使用
KR20110040773A (ko) 인터루킨-21 수용체 결합 단백질
KR20240004694A (ko) 항체
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK1157220A (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
HK40019833A (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid